Pyrazolopiperidine compounds as CCR1 receptor antagonists

US8546442B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Rajashekhar Betageri · Bethel, US
• Brian Nicholas Cook · Danbury, US
• Darren DiSalvo · New Milford, US
• Christian Harcken · New Milford, US
• Daniel Kuzmich · Clovis, US
• Pingrong Liu · Southbury, US
• John Lord · New York, US
• Can Mao · Philadelphia, US
• Hossein Razavi · Danbury, US

Key dates

• Filing date: Dec 16, 2011
• Grant date: Oct 1, 2013
• Expiry date: Mar 21, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are methods of making and methods of using same.